The discrepancies between in vitro and in vivo models, as well as the gap between these models and human tauopathies, highlight a critical challenge for drug discovery, as compounds that inhibit tau aggregation in vitro may not have the same efficacy or mechanism of action in a living organism. Here, MAPT is linked to tauopathy.